Evan Lippman - Alnylam Pharmaceuticals Chief Officer
| ALNY Stock | USD 253.07 0.67 0.26% |
Executive
Evan Lippman is Chief Officer of Alnylam Pharmaceuticals
| Address | 675 West Kendall Street, Cambridge, MA, United States, 02142 |
| Phone | 617 551 8200 |
| Web | https://www.alnylam.com |
Alnylam Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0292) % which means that it has lost $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (15.0066) %, meaning that it created substantial loss on money invested by shareholders. Alnylam Pharmaceuticals' management efficiency ratios could be used to measure how well Alnylam Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 2.10 in 2024, whereas Return On Tangible Assets are likely to drop (0.15) in 2024. At this time, Alnylam Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 889.5 M in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (547.6 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Morrissey | Incyte | 60 | |
| Linda JD | Wave Life Sciences | N/A | |
| Karen Lewis | Apellis Pharmaceuticals | 51 | |
| Debra DursoBumpus | Blueprint Medicines Corp | 54 | |
| Hubert MD | Krystal Biotech | 55 | |
| Anne MD | Exelixis | N/A | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Daryn Lewis | Wave Life Sciences | N/A | |
| Steven MD | Incyte | 57 | |
| Karah JD | Ultragenyx | 46 | |
| Jeffrey JD | Exelixis | 55 | |
| Ben Strain | Incyte | N/A | |
| Gerard Platenburg | ProQR Therapeutics BV | 60 | |
| Paul JD | Ultragenyx | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Prof MD | Day One Biopharmaceuticals | 55 | |
| David Chien | Krystal Biotech | N/A | |
| Kate Rausch | Wave Life Sciences | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Lukas MD | Apellis Pharmaceuticals | 53 | |
| Arjun Natesan | Ultragenyx | N/A | |
Management Performance
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 |
Alnylam Pharmaceuticals Leadership Team
Elected by the shareholders, the Alnylam Pharmaceuticals' board of directors comprises two types of representatives: Alnylam Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alnylam. The board's role is to monitor Alnylam Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alnylam Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alnylam Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saraswathy Nochur, Equity Diversity | ||
| Indrani JD, Executive Secretary | ||
| Evan Lippman, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Piyush JD, Chief Officer | ||
| Alfred Boyle, Chief Officer | ||
| Timothy Maines, Chief Officer | ||
| Kevin Fitzgerald, Senior Vice President Chief Scientific Officer | ||
| Michael BA, Ex Chairman | ||
| Pushkal MD, Chief Affairs | ||
| Tolga MBA, Executive Officer | ||
| Muthiah Manoharan, Senior Board | ||
| Christine Lindenboom, Senior Communications | ||
| MBChB MBA, CEO Director | ||
| MBA MBA, CEO Director | ||
| Kelley Boucher, Chief Human Resource Officer, Senior Vice President | ||
| Jeffrey MBA, CFO VP | ||
| Evan MBA, Chief Officer |
Alnylam Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alnylam Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -15.01 | ||||
| Return On Asset | -0.0292 | ||||
| Profit Margin | (0.16) % | ||||
| Operating Margin | (0.15) % | ||||
| Current Valuation | 31.16 B | ||||
| Shares Outstanding | 128.98 M | ||||
| Shares Owned By Insiders | 0.40 % | ||||
| Shares Owned By Institutions | 98.09 % | ||||
| Number Of Shares Shorted | 3.74 M | ||||
| Price To Earning | (22.92) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.